We've updated our Privacy Policy. Questions? Email us any time at privacy@ground.newsWe've updated our Privacy Policy with additional info on research surveys, our browser extension, cookie management, and ad performance measurement. Questions? Email us any time at privacy@ground.news
(MedPage Today) -- Shanghai-based biotech company HuidaGene Therapeutics disclosed the death of a child 1 year ago in a trial of an investigational gene-editing therapy for Duchenne muscular dystrophy.
Semaglutide (Wegovy) attenuated a proteomics...